CSL Behring has shared positive four-year results from a late-stage study of its haemophilia B gene therapy Hemgenix ...

“CSL delivered a solid result for the first half of the 2025 financial year led by CSL Behring. Strong demand for many of our market-leading therapies has translated into sales growth, particularly in ...

Narrow-moat CSL reiterated fiscal 2025 guidance for constant-currency group net profit after tax before amortization, or NPATA, of USD 3.2 billion to­ USD 3.3 billion, implying 1 ...

Antibody therapy Mim8 was found to be safe and effective for controlling bleeds in children with hemophilia A in a Phase 3 ...

CSL consistency isn’t winning over investors, Ryan Stokes explains the new dump truck dance, and Macquarie’s return on equity ...

Pfizer terminated partnership with Sangamo on hemophilia A gene therapy despite positive Phase 3 data. Find out why SGMO ...

Revenue from CSL's flu vaccine-making business dropped sharply in the first half of the financial year amid a significant ...

Revenue from CSL's flu vaccine-making business dropped sharply in the first half of the financial year amid a significant ...

The Business Research Company Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

Using “cure” to refer to “obtaining a normal life” also fits — if you ignore previously lost education, career opportunities ...

Data from the Phase III FRONTIER3 trial found that 98% of caregivers prefer Mim8 for hemophilia A over other treatments.

Novo Nordisk today announced interim results from the phase 3 FRONTIER3 trial of 70 children (aged 1-11 years old) with haemophilia A with and without inhibitors. The trial initially assessed ...